Expression of tumor necrosis factor-alpha receptor 2 and interleukin-1 in middle ear cholesteatoma
Abstract
Background/Aim. Cholesteatoma is characterized by progressive growth with the erosion of surrounding bone due to pressure effects, enzymatic activity and activation of osteoclasts. The aim of this study was to examine the expression levels of tumor necrosis factor (TNF)-alpha receptor 2 (TNF R2) and interleukin-1 (IL-1) in chronic otitis media (COM) with and without acquired cholesteatoma and correlate them with the degree of bone destruction. Methods. The study included 178 patients of both sexes, aged 5–75 years, who underwent microsurgical treatment for COM, with and without cholesteatoma at the Ear, Nose and Throat Department, University Clinical Center of Republika Srpska (UCC RS), Banja Luka from 2015 to 2018. Based on cholesteatoma presence, the patients with COM were divided into two groups: with cholesteatoma (CCOM) (n = 97) and without cholesteatoma (COMWC) (n = 81). Samples of cholesteatoma perimatrix in the CCOM group and tympanic cavity inflamed mucosa in the COMWC group were collected intraoperatively. Intraoperative exploration of the middle ear included the status of the ossicular chain, individual ossicles, osseous walls of the external auditory canal (EAC) and tympanic cavity. Expression levels of TNF R2 and IL-1 were investigated by immunohistochemical analysis of tissue samples obtained during ear surgery. Results. The correlation between the level of osteodestruction and the presence of cholesteatoma was significant (p < 0.01). Elevated expression levels of TNF R2 and IL-1 were most frequent in CCOM patients with osteodestruction. The probability of osteodestruction of EAC and tympanic cavity walls was significantly higher in patients with high TNF R2 expression (p < 0.05). With respect to IL-1 expression levels, no significant correlation with the described pathomorphological changes was observed. Correlation between TNF R2 and IL-1 expressions and ossicular chain destruction was significant (p < 0.01). Conclusion. Cholesteatoma presence and elevated expression levels of TNF R2 and IL-1 in COM patients are significantly correlated. Expression levels of TNF R2 and IL-1 in acquired cholesteatoma tissue have a potential clinical significance for the occurrence of bone destruction compared to expression levels in inflamed mucosa of the tympanic cavity.
References
Merchant SN, McKenna MJ, Rosowski JJ. Current status and future challenges of tympanoplasty. Eur Arch Otorhinolaryngol 1998; 255(5): 221–8.
Penido Nde O, Borin A, Iha LC, Suguri VM, Onishi E, Fukuda Y, et al. Intracranial complications of otitis media: 15 years of experience in 33 patients. Otolaryngol Head Nec Surg 2005; 132(1): 37–42.
Semaan MT, Megerian CA. The pathophysiology of cholesteatoma. Otolaryngol Clinic North Am 2006; 39(6): 1143‒
Kemppainen HO, Puhakka HJ, Laippala PJ, Sipilä MM, Manninen MP, Karma PH. Epidemiology and aetiology of middle ear cholesteatoma. Acta Otolaryngol 1999; 119(5): 568‒
Frickmann H, Zautner AE. Cholesteatoma - A Potential Consequence of Chronic Middle Ear Inflammation. Otolaryngology 2012; S5: DOI: 10.4172/2161-119X.S5-001.
Bennett M, Warren F, Jackson GC, Kaylie D. Congenital cholesteatoma: theories, facts, and 53 patients. Otolaryngol Clin North Am 2006; 39(6): 1081‒
Friedland DR, Eernisse R, Erbe C, Gupta N, Cioffi JA. Cholesteatoma growth and proliferation: posttranscriptional regulation by microRNA-21. Otol Neurotol 2009; 30(7): 998‒
Shin SH, Shim JH, Lee HK. Classification of external auditory canal cholesteatoma by computed tomography. Clin Exp Otorhinolaryngol 2010; 3(1): 24‒
Byun JY, Yune TY, Lee JY, Yeo SG, Park MS. Expression of CYLD and NF-kappa B in human cholesteatoma epithelium. Mediators Inflamm 2010; 2010: 796315.
Alves AL, Ribeiro FAQ. The role of cytokines in acquired middle ear cholesteatoma: literature review. Braz J Otorhinolaryngol 2004; 70(6): 813‒ (Portuguese)
Vitale RF, Ribeiro FAQ. The role of tumor necrosis factor-alpha (TNF-alpha) in bone resorption present in middle ear cholesteatoma. Braz J Otorhinolaryngol 2007; 73(1): 123‒ (Portuguese)
Bingham CO. The pathogenesis of rheumatoid arthritis: pivotal citokynes involved in bone degradation and inflammation. J Rheumatol Suppl 2002; 65: 3–9.
Shiwa M, Kojima H, Kamide Y, Moriyama H. Involvement of interleukin-1 in middle ear cholesteatoma. Am J Otolaryngol 1995; 16(5): 319–24.
Kim CS, Lee CH, Chung JW, Kim CD. Interleukin-1 alpha, interleukin-1 beta and interleukin-8 gene expression in human aural cholesteatomas. Acta Otolaryngol 1996; 116(2): 302–6.
Didierjean L, Salomon D, Mérot Y, Siegenthaler G, Shaw A, Dayer JM, et al. Localization and characterization of the interleukin 1 immunoreactive pool (IL-1 alpha and beta forms) in normal human epidermis. J Invest Dermatol 1989; 92(6): 809–16.
Mills RP, Padgham ND. Management of childhood cholesteatoma. J Laryngol Otol 1991; 105(5): 343–5.
Hamed MA, Nakata S, Sayed RH, Ueda H, Badawy BS, Nishimura Y, et al. Pathogenesis and Bone Resorption in Acquired Cholesteatoma: Current Knowledge and Future Prospectives. Clin Exp Otorhinolaryngol 2016; 9(4): 298‒
Kreutzer DL, Yellon RF, Leonard G, Marucha PT, Craven R, Carpenter RJ, et al. Characterization of cytokines present in middle ear effusions. Laryngoscope 1991; 101(2): 165‒
Assuma R, Oates T, Cochram D, Amar S, Graves DT. IL-1 and TNF antagonists inhibit the inflammatory response and bone loss in experimental periodontitis. J Immunol 1998; 160(1): 403‒
Olszewska E, Wagner M, Bernal-Sprekelson M, Ebmeyer J, Dazert S, Hildmann H, et al. Etiopathogenesis of cholesteatoma. Eur Arch Otorhinolaryngol 2004; 261(1): 6‒
Maniu A, Harabagiu O, Perde Schrepler M, Catana A, Fanuta B, Mogoanta CA. Molecular biology of cholesteatoma. Rom J Morphol Embryol 2014; 55(1): 7‒
Kawai T, Matsuyama T, Hosokawa, Makihira S, Seki M, Karimbux NY, et al. B and T lymphocytes are the primary sources of RANKL in the bone resorptive lesion of periodontal disease. Am J Pathol 2006; 169(3): 987‒
Louw L. Acquired cholesteatoma pathogenesis: stepwise explanations. J Laryngol Otol 2010; 124(6): 587‒
Yetiser S, Satar B, Aydin N. Expression of epidermal growth factor, tumor necrosis factor-alpha, and interleukin-1alpha in chronic otitis media with or without cholesteatoma. Otol Neurotol 2002; 23(5): 647‒
Akimoto R, Pawankar R, Yagi T, Baba S. Acquired and congenital cholesteatoma: determination of tumor necrosis factor-alpha, intercellular adhesion molecule-1, interleukin-1-alpha and lymphocyte functional antigen-1 in the inflammatory process. ORL J Otorhinolaryngol Relat Spec 2000; 62(5): 257‒
Li Z, Li X, Liu G. A study on expression of tumor necrosis factor alpha in middle ear cholesteatoma and its effect on bone destruction. Lin Chuang Er Bi Yan Hou Ke Za Zhi 2001; 15(2): 66‒
Welkoborsky HJ. Current concepts of the pathogenesis of acquired middle ear cholesteatoma. Laryngorhinootologie 2011; 90(1): 38‒48; quiz 49‒
Kuczkowski J, Sakowicz-Burkiewicz M, Izycka-Swieszewska E, Mikaszewski B, Pawelczyk T. Expression of tumor necrosis factor-α, interleukin-1α, interleukin-6 and interleukin-10 in chronic otitis media with bone osteolysis. ORL J Otorhinolaryngol Relat Spec 2011; 73(2): 93‒
Amar MS, Wishahi HF, Zakhary MM. Clinical and biochemical studies of bone destruction in cholesteatoma. J Laryngol Otol 1996; 110(6): 534‒